66298-49-5 Usage
Uses
Used in Organic Synthesis:
4,6-DIIODO-2-METHYLPYRIMIDINE is used as a reagent in organic synthesis for its ability to undergo various chemical transformations. It is particularly favored in the preparation of pharmaceuticals and agrochemicals due to its versatility in creating a wide range of complex organic molecules.
Used in Specialty Chemicals Production:
4,6-DIIODO-2-METHYLPYRIMIDINE is also utilized in the production of dyes, pigments, and other specialty chemicals, where its unique structural features contribute to the desired properties of the final products.
Used in Research and Development:
4,6-DIIODO-2-METHYLPYRIMIDINE serves as a key intermediate in the development of new chemical entities, including potential therapeutic agents and novel materials, due to its reactivity and structural characteristics.
It is crucial to handle 4,6-DIIODO-2-METHYLPYRIMIDINE with care, given its potentially hazardous properties such as toxicity and irritancy, ensuring safety in both laboratory and industrial settings.
Check Digit Verification of cas no
The CAS Registry Mumber 66298-49-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,2,9 and 8 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 66298-49:
(7*6)+(6*6)+(5*2)+(4*9)+(3*8)+(2*4)+(1*9)=165
165 % 10 = 5
So 66298-49-5 is a valid CAS Registry Number.
InChI:InChI=1/C5H4I2N2/c1-3-8-4(6)2-5(7)9-3/h2H,1H3
66298-49-5Relevant academic research and scientific papers
COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY
-
Page/Page column 46; 57; 58, (2018/09/08)
Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES
-
Page/Page column 66, (2010/12/31)
The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
CALCIUM CHANNEL ANTAGONISTS
-
Page/Page column 33, (2010/11/27)
The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
CALCIUM CHANNEL ANTAGONISTS
-
Page/Page column 8, (2010/11/28)
The present invention provides novel calcium channel antagonists, and methods of treating disease sates using the novel antagonists.
